Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|June 27, 2018
Data Integrity Issues Found at China Facility
Author(s)Pharmaceutical Technology Editors
FDA sent a warning letter to Henan Lihua Pharmaceutical Co. Ltd. after inspectors found the company failed to ensure the accuracy of its data.
Advertisement
FDA sent a
The agency stated in the letter that the company failed to review and approve quality-related documents. Blank batch manufacturing records and record issuance stamps were observed in the workshop office.
“These blank records and stamps were uncontrolled, although your standard operating procedure states that your quality unit is responsible for release of blank CGMP records. Your quality unit failed to control these records to assure that information entered on these forms is accurate and reliable. The use of uncontrolled records without quality unit review and approval poses a risk to data integrity and adequate assurance of product quality. FDA recommends that, if used, blank forms be controlled by the quality unit or by another document control method,” FDA stated.
The company also failed to maintain complete laboratory test data, according to FDA. “It is essential to retain raw data to ensure the ability to reconstruct CGMP activities and to review raw data, as necessary, for CGMP control testing,” the agency stated. In response to FDA, the company plans to replace instruments and software. The agency, however, stated in the warning letter that the company must also implement appropriate procedures and systems to ensure that data are retained.
FDA asked that the company provide the agency with a comprehensive investigation into the inaccuracies in data records and reporting, a risk assessment of the potential effects of the data failures on product quality, and a management strategy that includes corrective actions and preventive actions.
The agency placed the company on Import Alert 66-40 on March 29, 2018 and advised the company that approval of new applications or supplements that list the firm as a drug manufacturer may be withheld.
Source:
Advertisement
Related to this article
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
Advertisement
Advertisement